- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.06. | BofA raises Tyra Biosciences stock price target on safety outlook | 3 | Investing.com | ||
| 10.06. | BofA hebt Kursziel für Tyra Biosciences nach positiven Signalen zur Sicherheit an | 1 | Investing.com Deutsch | ||
| 04.06. | Raymond James reiterates Strong Buy on Tyra Biosciences stock amid recent weakness | 1 | Investing.com | ||
| 02.06. | Tyra Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.05. | Wolfe Research initiates Tyra Biosciences stock at Peerperform | 1 | Investing.com | ||
| TYRA BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 13.05. | Tyra Biosciences GAAP EPS of -$0.64 | 2 | Seeking Alpha | ||
| 13.05. | Tyra Biosciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | Tyra Biosciences, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 10.05. | Tyra Biosciences: Anleger blicken über Quartalszahlen hinaus auf entscheidende Studiendaten zu Blasenkrebs | - | Investing.com Deutsch | ||
| 22.04. | Tyra Biosciences: Board Appointment Of Habib Dable Supports Next Phase Of Growth | 1 | pulse2.com | ||
| 17.04. | Cantor Fitzgerald reiterates Tyra Biosciences stock rating | 2 | Investing.com | ||
| 17.04. | Cantor Fitzgerald bestätigt 'Overweight'-Rating für Tyra Biosciences | 2 | Investing.com Deutsch | ||
| 17.04. | Tyra Biosciences beruft Habib Dable in den Verwaltungsrat | 2 | Investing.com Deutsch | ||
| 17.04. | Tyra Biosciences adds Habib Dable to board of directors | 1 | Investing.com | ||
| 17.04. | Tyra Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 15.04. | This Tyra Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday | 1 | Benzinga.com | ||
| 02.04. | Tyra Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.03. | Tyra Biosciences platziert Aktienpaket im Wert von 126 Mio. US-Dollar in Block-Trade | 3 | Investing.com Deutsch | ||
| 04.03. | Tyra Biosciences: Aktie auf Rekordhoch nach Kursrally von über 200 % | 5 | Investing.com Deutsch | ||
| 03.03. | Tyra Biosciences: H.C. Wainwright bekräftigt "Buy"-Rating und Kursziel von 45 Dollar | 1 | Investing.com Deutsch |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 36,670 | +10,62 % | Dividendenbekanntmachungen (07.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABC ARBITRAGE SA FR0004040608 - 0,04 EUR ACCIONA SA ES0125220311 - 5,7486 EUR AMICA SA PLAMICA00010 2,5 PLN 0,5829 EUR ANY BIZTONSAGI... ► Artikel lesen | |
| VIRAX BIOLABS GROUP | 6,340 | 0,00 % | Morning Market Movers: Virax Biolabs, Aimei Health Technology, Sadot Group, Ionis Pharmaceuticals See Big Swings | BEIJING (dpa-AFX) - At 8:35 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| COGENT BIOSCIENCES | 40,470 | +1,25 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 133,57 | +0,24 % | AbbVie setzt mit Apogee-Übernahme neuen Akzent im Wettlauf um Blockbuster-Biologika | AbbVie stärkt mit der geplanten Übernahme von Apogee Therapeutics seine Position im Markt für Immunologie-Biologika und vertieft damit eine ohnehin schon dominante Wettbewerbsstellung. Der Deal zielt... ► Artikel lesen | |
| ABSCI | 11,465 | 0,00 % | Morning Market Movers: Cuprina Holdings, CEA Industries, Absci, The Wendy's Company See Big Swings | MEMPHIS (dpa-AFX) - At 7:10 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 64,15 | -5,29 % | Tarsus buys iRenix Medical for $75M, gains late-stage eye care asset IRX-101 | ||
| BEAM THERAPEUTICS | 35,840 | -2,82 % | BofA bestätigt Kaufempfehlung für Beam Therapeutics nach Schiedsspruch | ||
| VERA THERAPEUTICS | 42,420 | 0,00 % | Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner | BRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Officer... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 48,380 | +4,49 % | Oppenheimer initiates Edgewise Therapeutics stock with outperform rating | ||
| ERASCA | 19,180 | +1,64 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,765 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 28,770 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months | FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Application supported by positive results from Phase 2 open-label INTEGUMENT-INFANT study and Phase 1 open-label... ► Artikel lesen | |
| ALUMIS | 30,270 | +1,78 % | Alumis Aktie erreicht Rekordhoch bei 30,67 USD | ||
| RELAY THERAPEUTICS | 20,750 | 0,00 % | JPMorgan stuft Relay Therapeutics zum Start mit "Overweight" ein | ||
| CG ONCOLOGY | 73,34 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen |
TYRA BIOSCIENCES INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 33,010 Euro und damit +1,35 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TYRA BIOSCIENCES INC finden Sie auf Wallstreet Online.